Oral Targeted Drug Delivery Systems: Gastric Retention Devices

Omidian, Hossein; Park, Kinam

doi:10.1002/9780470640487.ch12

Cited by 7 publications

(2 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to higher degree of gut motility in case of fasted state, the chyme leaves the stomach anytime between few minutes to approximately 3 h (49). Therefore in the fasted rats, the tablet was located in the lower segment of the large intestine approximately within 4 h of administration.…”

Section: In Vivo Studies On Adhesion Of the Tablet In The Gastrointesmentioning

confidence: 99%

A Novel Synergistic Galactomannan-Based Unit Dosage Form for Sustained Release of Acarbose

Kumar

Sinha

2012

AAPS PharmSciTech

View full text Add to dashboard Cite

Abstract. In the current study, the potential of a novel combination of a galactomannan with acarbose (100 mg) was evaluated for attaining a desired hypoglycaemic effect over a prolonged period of time. Three major antidiabetic galactomannans viz., fenugreek gum, boswellia gum, and locust bean gum were selected in order to achieve a synergistic effect in the treatment alongwith retardation in drug release. In vitro studies indicated that batches containing various proportions of fenugreek gum (AF40-60) were able to control drug release for a longer duration of approximately 10-12 h. In contrast, the matrices prepared using boswellia and locust bean gum were able to sustain the release for relatively shorter durations. Drug release mainly followed first-order release kinetics owing to the highly soluble nature of the drug. In vivo study depicted a significant reduction (p<0.001) in the postprandial blood glucose and triglyceride levels in the diabetic rats on treatment with formulation AF40. Thus, the developed system provides a better control of the postprandial glycaemic levels and it also obviates the need of conventional multiple dosing of acarbose. Furthermore, it also reduces the occurrence of side effects like diarrhea and loss of appetite.

show abstract

Section: In Vivo Studies On Adhesion Of the Tablet In The Gastrointesmentioning

confidence: 99%

A Novel Synergistic Galactomannan-Based Unit Dosage Form for Sustained Release of Acarbose

Kumar

Sinha

2012

AAPS PharmSciTech

View full text Add to dashboard Cite

show abstract

“…Modified release drug delivery systems have attracted a great deal of interest in recent decades. In the field of oral drug delivery, one of the main factors determining the extent of absorption and duration of effect is the time that drug is present in the site of absorption ( 1 ). Modified release drug delivery systems alter the time course of drug release and/or retain the system at the site of absorption for a longer period of time ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Formulation and in vitro evaluation of a fast-disintegrating/sustained dual release bucoadhesive bilayer tablet of captopril for treatment of hypertension crises

Abbasi¹,

Yousefi²,

Ansari³

et al. 2016

Res Pharma Sci

View full text Add to dashboard Cite

Hypertension crisis is one of the main health problems and its effective treatment is of high importance. For this purpose, fast-disintegrating and sustained release formulations of captopril, as a drug of choice, were prepared using conventional mucoadhesive polymers hydroxypropyl methylcellulose (HPMC), sodium carboxymethyl cellulose (Na-CMC), hydroxypropyl cellulose (HPC), Carbopol 934 (CP934) and sodium alginate (Na-alg). The optimum sustained release formulations were selected based on mean dissolution time (MDT). The swellability and mucoadhesive properties of selected formulations were assessed and compared. A direct relationship between swelling and release rates/adhesiveness of sustained release formulations was observed. The results showed that formulations containing combination of CP934 and cellulose-based polymers had the highest swellability, sustainability and adhesion strength. These formulations prolonged drug release up to 8 h showing good fitness to Korsemeyer-Peppas model. Moreover, the adopted fast-disintegrating tablet could release up to 100% of drug within 3 min in oral pH. Finally, a dual fast-disintegrating/sustained release bucoadhesive bilayer tablet consisting of optimized formulations was prepared releasing 30% of the drug initially within 15 min and the remaining up to 8 h which could be considered as an appropriate formulation for the treatment of hypertension crises.

show abstract